Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
5.75
-0.16 (-2.71%)
At close: Dec 5, 2025, 4:00 PM EST
5.74
-0.01 (-0.17%)
After-hours: Dec 5, 2025, 6:15 PM EST
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 279 employees as of December 31, 2024. The number of employees decreased by 46 or -14.15% compared to the previous year.
Employees
279
Change (1Y)
-46
Growth (1Y)
-14.15%
Revenue / Employee
$510,860
Profits / Employee
-$446,670
Market Cap
98.04M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KPTI News
- 4 days ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 days ago - Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference - PRNewsWire
- 4 weeks ago - Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress - PRNewsWire
- 5 weeks ago - Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 - PRNewsWire
- 2 months ago - Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026 - Benzinga
- 2 months ago - Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis - PRNewsWire
- 3 months ago - Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis - PRNewsWire